We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EVER:NASDAQEverQuote, Inc. Analysis

Data as of 2026-04-01 - not real-time

$14.90

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

EverQuote posted a *38% revenue jump* to $692.5 M in 2025, driven by new AI‑enabled carrier partnerships, and it now targets $1 B in sales. The company’s fundamentals are striking: a **gross margin of 97%**, operating margin of 9.5%, ROE of 53%, and a trailing PE of 5.66 versus an industry average of 17.25 signal strong profitability and deep undervaluation. With a DCF‑derived fair value of $69.97, the stock trades at a **62% discount** to intrinsic worth, and the upside/downside metric corroborates this gap. Technically, the price sits just above the 14.84 $ support level but below the 20‑day SMA (15.89 $) and 50‑day SMA (17.30 $), the RSI is at 38 indicating modest momentum, while the MACD histogram turned positive, giving a *bullish* signal amid an overall bearish trend.
Given the **stable volume**, low debt, and robust cash flow generation, the primary risks stem from high 30‑day volatility (≈47%) and a beta above 1, which could amplify market swings. Nevertheless, the combination of rapid top‑line growth, exceptional margins, and a sizable valuation cushion positions EverQuote as a compelling **buy** for investors with medium‑ to long‑term horizons.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering near support at $14.84
  • Bearish SMA alignment and modest RSI
  • Elevated short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • 32.5% YoY revenue growth and AI‑driven carrier deals
  • Substantial valuation gap (price vs DCF fair value)
  • Strong cash generation and low leverage

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Scalable online insurance marketplace model
  • High ROE (53%) and durable profit margins
  • Long‑term upside potential exceeding 60% based on intrinsic valuation

Key Metrics & Analysis

Financial Health

Revenue Growth32.50%
Profit Margin14.34%
P/E Ratio5.7
ROE53.19%
ROA15.48%
Debt/Equity1.08
P/B Ratio2.3
Op. Cash Flow$95.4M
Free Cash Flow$63.9M
Industry P/E17.3

Technical Analysis

TrendBearish
RSI38.1
Support$14.84
Resistance$17.59
MA 20$15.89
MA 50$17.30
MA 200$22.54
MACDBullish
VolumeStable
Fear & Greed Index77.14

Valuation

Fair Value$69.97
Target Price$24.17
Upside/Downside62.25%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.08
Volatility47.36%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.